Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study

BACKGROUND: Short-term infusions of dinutuximab beta plus isotretinoin and cytokines administered in previous immunotherapy studies in neuroblastoma were associated with severe pain. Here, long-term, continuous infusion of single-agent dinutuximab beta was evaluated in patients with relapsed/refract...

Descripción completa

Detalles Bibliográficos
Autores principales: Lode, Holger N., Ehlert, Karoline, Huber, Stephanie, Troschke-Meurer, Sascha, Siebert, Nikolai, Zumpe, Maxi, Loibner, Hans, Ladenstein, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667538/
https://www.ncbi.nlm.nih.gov/pubmed/37813959
http://dx.doi.org/10.1038/s41416-023-02457-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667538/
https://www.ncbi.nlm.nih.gov/pubmed/37813959
http://dx.doi.org/10.1038/s41416-023-02457-x

Ejemplares similares